

SEP acquires Contura A/S

Speciality European Pharma Limited (SEP), is pleased to announce that on 30 April 2013 it completed the acquisition of Contura A/S, the Danish holding company of Contura International A/S and Contura Inc. (together "the Contura Group").

The Contura Group is headquartered in Copenhagen, Denmark and operates from a 1,500 square metre manufacturing facility in the city. Founded in the year 2000, the Contura Group has developed a patented hydrogel technology. It currently has three marketed medical devices, Bulkamid[®], Aquamid[®], Aquamid[®] Reconstruction, each of which are sold through distribution partners. In addition to its marketed medical devices, the Contura Group has a number of development programmes for new products that will utilise its hydrogel technology, including a potential new treatment for osteoarthritis and a novel veterinary product.

Financial details of the transaction were not disclosed.

Commenting on the acquisition, Patrick Banks, Chief Executive Officer of SEP, said:

"This acquisition further cements SEP's position in the urology and urogynaecology markets. Strategically, the acquisition makes sense for SEP since:

- i. SEP and the Contura Group are complimentary. SEP brings commercial marketing infrastructure to the combined company, while the Contura Group brings new products, development opportunities and considerable manufacturing expertise and capacity;
- ii. SEP aims to sell health care products to its target market, the urologist and urogynaecologist. SEP is agnostic to whether such products are pharmaceuticals or medical devices, though the regulatory pathway for the two product types differ significantly. The acquisition of the Contura Group brings medical device expertise to SEP, therefore opening up the opportunity to develop, acquire or license new medical devices in the future.
- iii. One of the Contura Group's currently marketed products, Bulkamid[®], is a clear complimentary sale for SEP. Bulkamid[®], a product for stress urinary incontinence, will be sold to the same customer base as the company's over active bladder product, Regurin XL[®]."

About Bulkamid[®]

Bulkamid[®] is a homogenous hydrophilic hydrogel used in the treatment of female stress urinary incontinence. The product was granted CE approval in 2003 and is currently sold in more than 20 countries worldwide. Bulkamid[®] is delivered to the patient under endoscopic control using the Bulkamid[®] Urethral Bulking System.

About Aquamid®

Aquamid® is a non-absorbable hydrogel that is used to rejuvenate and contour the face. The product does this by restoring lost volume or by adding extra volume where required. As the product does not degrade, the aesthetic results remain for years. The product was granted CE approval in 2001.

About Aquamid® Reconstruction

Aquamid® Reconstruction is a non-absorbable high viscoelastic hydrogel for soft tissue augmentation. The product is used where the areas to be treated require more volume or where there is a need for a higher elasticity product. The product has been successfully used in patients for lipoatrophy and rhinoplasty, amongst others and its safety and efficacy data show excellent results over a period of more than 10 years. The product was granted CE approval in 2004.

About SEP

SEP is the parent company of a European group which specialises in the distribution and sale of healthcare products, both pharmaceuticals and medical devices, focused primarily upon the fields of urology and urogynaecology. Its lead products, prior to its acquisition of Contura were:

Mitem®
Regurin® XL

SEP was founded in 2006 and built an experienced and accomplished management team. With the acquisition of Contura, two further marketed products, Bulkamid® and Aquamid®, are added to its product offering. SEP has established a sales and marketing infrastructure in the leading European markets, either through its own sales force or through distribution partners. SEP has offices in the UK, Germany, France and Italy. The acquisition of Contura brings with it offices and a manufacturing site in Denmark

-ENDS-

For further information please contact:

SEP
Patrick Banks, Chief Executive Officer

Tel: +44 (0)20 7421 7400